Global Acromegaly and Gigantism Drugs Market 2018-2022

  • ID: 4463447
  • Report
  • Region: Global
  • 100 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5
About Acromegaly and Gigantism Drugs

The acromegaly and gigantism are GH-related diseases. Acromegaly disease occurs in adults while gigantism occurs in children.

The analysts forecast the global acromegaly and gigantism drugs market to grow at a CAGR of 3.03% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global acromegaly and gigantism drugs market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of acromegaly and gigantism drugs.

The market is divided into the following segments based on geography:
  • Americas
  • APAC
  • EMEA
The report, Global Acromegaly and Gigantism Drugs Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Ipsen
  • Novartis
  • Pfizer
Market drivers
  • Strong pipeline
  • For a full, detailed list, view the full report
Market challenges
  • Difficulty in diagnosis
  • For a full, detailed list, view the full report
Market trends
  • Growing popularity of drugs over surgeries
  • For a full, detailed list, view the full report
Key questions answered in this report
  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: INTRODUCTION
  • Market outline
PART 05: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 06: MARKET SIZING
  • Market definition
  • Market sizing
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: PIPELINE ANALYSIS

PART 09: MARKET SEGMENTATION BY DRUG CLASS
  • Segmentation by drug class
  • Comparison by drug class
  • Somatostatin analogs - Market size and forecast 2017-2022
  • GH receptor antagonists - Market size and forecast 2017-2022
  • Dopamine agonists - Market size and forecast 2017-2022
  • Recombinant human IGF-1 - Market size and forecast 2017-2022
  • Market opportunity by product
PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 14: MARKET TRENDS
  • Growing popularity of drugs over surgeries
  • Focus on long-acting novel formulations
PART 15: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 16: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Ipsen
  • Novartis
  • Pfizer
PART 17: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global acromegaly and gigantism drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2017
Exhibit 07: Validation techniques employed for market sizing 2017
Exhibit 08: Global acromegaly and gigantism drugs market 2017-2022 ($ mn)
Exhibit 09: Global acromegaly and gigantism drugs market: Year-over-year (YoY) growth 2018-2022 (%)
Exhibit 10: Five forces analysis 2017
Exhibit 11: Five forces analysis 2022
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition - Five forces 2017
Exhibit 18: Pipeline landscape by development phase
Exhibit 19: Key clinical trials for global acromegaly and gigantism drugs market
Exhibit 20: Segmentation of global acromegaly and gigantism drugs market by drug class 2017-2022 (%)
Exhibit 21: Comparison by drug class
Exhibit 22: Somatostatin analogs - Market size and forecast 2017-2022 ($ mn)
Exhibit 23: Somatostatin analogs - YoY growth 2018-2022 (%)
Exhibit 24: GH receptor antagonists - Market size and forecast 2017-2022 ($ mn)
Exhibit 25: GH receptor antagonists - YoY growth 2018-2022 (%)
Exhibit 26: Dopamine agonists - Market size and forecast 2017-2022 ($ mn)
Exhibit 27: Dopamine agonists - YoY growth 2018-2022 (%)
Exhibit 28: Recombinant human IGF-1 - Market size and forecast 2017-2022 ($ mn)
Exhibit 29: Recombinant human IGF-1 - YoY growth 2018-2022 (%)
Exhibit 30: Market opportunity by product
Exhibit 31: Customer landscape
Exhibit 32: Segmentation of global acromegaly and gigantism drugs market by geography 2017-2022 (%)
Exhibit 33: Regional comparison
Exhibit 34: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 35: Americas - YoY growth 2018-2022 (%)
Exhibit 36: Top three countries in Americas
Exhibit 37: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 38: EMEA - YoY growth 2018-2022 (%)
Exhibit 39: Top three countries in EMEA
Exhibit 40: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 41: APAC - YoY growth 2018-2022 (%)
Exhibit 42: Top three countries in APAC
Exhibit 43: Market opportunity
Exhibit 44: Percentage increase in GDI of India, China, and US for 2011-2016
Exhibit 45: Vendor landscape
Exhibit 46: Landscape disruption
Exhibit 47: Vendors covered
Exhibit 48: Vendor classification
Exhibit 49: Market positioning of vendors
Exhibit 50: Ipsen - Vendor overview
Exhibit 51: Ipsen - Business segments
Exhibit 52: Ipsen - Organizational developments
Exhibit 53: Ipsen - Geographic focus
Exhibit 54: Ipsen - Segment focus
Exhibit 55: Ipsen - Key offerings
Exhibit 56: Ipsen- Key customers
Exhibit 57: Novartis - Vendor overview
Exhibit 58: Novartis - Business segments
Exhibit 59: Novartis - Organizational developments
Exhibit 60: Novartis - Geographic focus
Exhibit 61: Novartis - Segment focus
Exhibit 62: Novartis - Key offerings
Exhibit 63: Pfizer - Vendor overview
Exhibit 64: Pfizer - Business segments
Exhibit 65: Pfizer - Organizational developments
Exhibit 66: Pfizer - Geographic focus
Exhibit 67: Pfizer - Segment focus
Exhibit 68: Pfizer - Key offerings
Exhibit 69: Pfizer - Key customers
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
New Report Released: - Global Acromegaly and Gigantism Drugs Market 2018-2022

The author of the report recognizes the following companies as the key players in the global acromegaly and gigantism drugs market: Ipsen, Novartis, and Pfizer

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is growing popularity of drugs over surgeries. Although pharmacological therapies for acromegaly treatment have been there for more than a decade, the demand from individuals for these non-surgical options is increasing on a regular basis. The prime reason for the shift in choice can be attributed to low success rates of acromegaly surgeries. For instance, as per the NIH, in a study involving total 62 subjects, 31 subjects were treated by transsphenoidal surgery, and four subjects were cured. Out of these 31 subjects treated with transsphenoidal surgery, post-operative anterior pituitary hormone deficiency was seen in 10 subjects, and diabetes insipidus got developed in one subject.”

According to the report, one of the major drivers for this market is Strong pipeline. The presence of a large number of molecules in pipeline represents significant opportunities for market growth. Around 42.86% of the total pipeline molecules for acromegaly and gigantism are in Phase III stage of development and are expected to be launched during the forecast period. Companies are working toward the development of drugs that cater to the unmet medical needs for this condition. For instance, octreotide capsules by Chiasma and Pasireotide long-acting release (LAR) by Novartis for individuals with acromegaly who are inadequately treated with somatostatin analogs, and combination therapy of lanreotide autogel and pegvisomant by Ipsen are in Phase III stage of development for the treatment of acromegaly.

Further, the report states that one of the major factors hindering the growth of this market is Difficulty in diagnosis. In the last two decades, numerous important advancements took place in the domain such as the emergence of assays with improved sensitivity for IGF-1 and GH, development of automated software for evaluating physical changes associated with the disease, and widespread pituitary examination using magnetic resonance imaging (MRI). Despite all these advancements, acromegaly remains clinically under-diagnosed.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Ipsen
  • Novartis
  • Pfizer
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll